Literature DB >> 3745165

Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

J Gut, T Catin, P Dayer, T Kronbach, U Zanger, U A Meyer.   

Abstract

The debrisoquine/sparteine-type polymorphism of drug oxidation presumably is caused by the absence or deficiency of cytochrome P-450 (P-450) isozyme(s). Using bufuralol 1'-hydroxylation as a prototype reaction of this polymorphism, two functionally distinct forms, P-450 buf I and P-450 buf II, with identical apparent Mr of 50,000 were purified from liver microsomes of three different human livers. P-450 buf I exhibited a marked selectivity for the (+)-enantiomer of bufuralol ((-)/(+) ratio = 0.15), P-450 buf II was nonstereoselective((-)/(+) ratio = 1.03). The Km values for (-)- and (+)-bufuralol were 31 and 54 microM with P-450 buf I and 314 and 245 microM with P-450 buf II. P-450 buf II generated two other metabolites in addition to 1'-OH-bufuralol which were not observed with P-450 buf I. Using the inhibitor quinidine, a Ki of 0.06 microM was observed with P-450 buf I as opposed to 80 microM with P-450 buf II for bufuralol 1'-hydroxylation. A strong immunochemical relatedness of P-450 buf I and P-450 buf II was found since polyclonal antibodies against either form recognized the heterologous antigen to the same extent as the homologous antigen on Western blots and in immunoinhibition and in immunoprecipitation experiments. Cross-reactivity of these antibodies with a microsomal nonheme protein of unknown function (apparent Mr 50,000) also was noted. Western blots of microsomes of in vivo and in vitro phenotyped extensive and poor metabolizer individuals revealed no correlation of in vivo-determined metabolic ratio, microsomal activity, and amount of immunoreactive material. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol 1'-hydroxylation in microsomes of in vivo and in vitro phenotyped poor metabolizer individuals demonstrating that the residual activities are immunochemically related to the activities in extensive metabolizers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3745165

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.

Authors:  R R Meehan; J R Gosden; D Rout; N D Hastie; T Friedberg; M Adesnik; R Buckland; V van Heyningen; J Fletcher; N K Spurr
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

2.  Analysis of the transcripts of cytochrome P-450IID gene subfamily in bovine adrenal gland.

Authors:  Y Matsuo; K Iwahashi; Y Kawai; Y Ichikawa
Journal:  Histochemistry       Date:  1992-05

3.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

Authors:  S Kimura; M Umeno; R C Skoda; U A Meyer; F J Gonzalez
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

4.  Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Authors:  D Larrey; G Babany; M Tinel; E Freneaux; G Amouyal; F Habersetzer; P Letteron; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

5.  Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.

Authors:  M P Manns; E F Johnson; K J Griffin; E M Tan; K F Sullivan
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

6.  Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.

Authors:  J Turgeon; W E Evans; M V Relling; G R Wilkinson; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 7.  Cytochrome P450 research and The Journal of Biological Chemistry.

Authors:  F Peter Guengerich
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

8.  Human liver debrisoquine 4-hydroxylase: test for specificity toward various monooxygenase substrates and model of the active site.

Authors:  T Wolff; L M Distlerath; M T Worthington; F P Guengerich
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

9.  Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.

Authors:  T D Leemann; K P Devi; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

Authors:  U M Zanger; H P Hauri; J Loeper; J C Homberg; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.